Replies to post #48879 on Easton Pharmaceuticals, Inc. (EAPH)

[mckinley1]

In addition to EAPH acquisition negotiations being finalized to acquire 100% of BMV Medica SA de CV, Easton's two cancer drugs in process of being approved for sale by the Mexican Ministry of Health.

Easton is nearing completion on negotiations to acquire 100% of BMV Medica SA de CV and all of its assets and revenues. In addition, Easton and BMV have received a positive update and are anticipating a positive announcement towards the regulatory filing of Generic Cancer Drugs Paclitaxel and Docetaxel, currently licensed from BioLyse Pharma of St. Catherines, Ontario, Canada. Easton / BMV were awaiting the final testing document from BioLyse Pharma who is the manufacturer of the 2 Generic Cancer Drugs. The testing document required verification that the raw material (API) sourced from China has the appropriate GMP certification in Mexico clearing the way for the fast track filing to be submitted by Defi Latina — one of only a few authorized third-party reviewers licensed by the Ministry of Health in Mexico to review and pre-approve Regulatory dossiers prior to submission. As was the case with women’s diagnostic product, VS-Sense. The “fast-track” review process through authorized third-party reviewers can speed up approval times from several years to a few short months. VS-Sense was approved within 2 months of regulatory filing.

Easton / BMV acquired licensing and distribution rights from Canadian Drug Manufacturer BioLyse Pharma for generic cancer drugs Docetaxel and Paclitaxel for Mexico and Latin America. The country of origin for the generic cancer drugs is Canada, believed to be one of the top six in the World — along with the USA, Britain, Australia, France and Germany. Mexican Health Authorities traditionally have very few issues with pharmaceutical products manufactured in these countries therefore a fast track approval is possible with purchase orders and sales to shortly follow. The majority of sales in Mexico expected to be to the Mexican government hospitals and institutions. As Canada is part of the North American Free Trade Agreement (NAFTA), Canadian-manufactured pharmaceuticals qualify for the national tender program in Mexico, providing a major advantage over other non-NAFTA manufacturers. The “Docetaxel” market in Mexico is by itself worth tens of millions of dollars annually, and Easton / BMV expects to be able to garner 20% of that within a year of launch, growing to 30% within three years. The total generic cancer drug market in Mexico represents hundreds of millions of dollars.